Replimune Group Inc. (REPL) is doing cutting-edge work in the field of new cures for cancer. They are "pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the tumor locally, alter the tumor microenvironment, and ignite a powerful patient-specific immune response."
Let's check out the charts and indicators to see if the charts are also cutting edge.
In the daily bar chart of REPL, below, I can see a bottoming pattern playing out from February. Prices made a "left shoulder" in February/March. A "head" in May/June and a "right shoulder" in September. Using your imagination you can draw a horizontal line across $21 to show a "neckline."
The shares broke out to the upside earlier this month. Notice the very heavy trading volume to accompany the upside breakout -- this is "escape velocity" volume. The On-Balance-Volume (OBV) line declined into September and the "right shoulder" but the line has turned upwards in December to confirm the price gains.
The Moving Average Convergence Divergence (MACD) oscillator is bullish.